1346243-08-0

Upstream product

• 10272-07-8 3.5-dimethoxyaniline 
• 82031-32-1 7-bromo-1H-quinoxalin-2-one 
• 552846-17-0 tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate 
• 1346245-20-2 C₂₀H₂₀ClN₃O₂ 
• 1346245-13-3 3-chloro-N-(3,5-dimethoxyphenyl)quinoxalin-6-amine 
• 1346245-12-2 C₁₆H₁₅N₃O₃ 
• 1346245-21-3 C₂₈H₃₁N₅O₄ 
• 82031-32-1 2-hydroxy-7-bromoquinoxaline 
• 89891-65-6 7-bromo-2-chloroquinoxaline 
• 1196-57-2 2-hydroxyquinoxaline 
• 1346245-22-4 7-bromo-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]-quinoxaline 
• 1346246-09-0 N-(3,5-dimethoxyphenyl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)quinoxaline-6-amine 

Downstream Products

• 1346243-83-1 C₂₇H₃₁N₅O₃ 
• 1346243-90-0 C₂₆H₂₇N₅O₂ 
• 1346243-88-6 C₂₅H₂₈N₆O₄S 
• 1346243-82-0 C₂₅H₂₆BrN₅O₂ 
• 1346246-43-2 C₃₁H₄₁N₅O₃Si 
• 1346243-85-3 C₃₁H₃₈N₆O₃ 
• 1346243-30-8 C₂₆H₂₉N₅O₄ 
• 1346243-86-4 C₂₅H₂₇N₅O₃ 
• 1346243-91-1 C₂₆H₃₀N₆O₂ 
• 1346244-07-2 C₂₅H₂₆FN₅O₂ 

Relevant academic research and scientific papers

Double-target inhibitor targeting FGFR (fibroblast growth factor receptor) and HDAC (histone deacetylase) as well as preparation method and application thereof, pharmaceutical composition and medicament

The invention discloses a double-target inhibitor targeting FGFR (fibroblast growth factor receptor) and HDAC (histone deacetylase) as well as a preparation method and application thereof, a pharmaceutical composition and a medicament, and belongs to the

PYRAZOLYL QUINAZOLINE KINASE INHIBITORS

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.